
Fibralign Corporation
Advanced biomedical devices company.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | Seed | ||
Total Funding | 000k |
Related Content
Fibralign Corporation is a commercial-stage medical device company that emerged as a spin-out from Stanford University in 2007. The company focuses on developing and producing therapeutic biomedical devices to address significant unmet medical needs. It operates from its headquarters and ISO-certified manufacturing facility in the San Francisco Bay Area. Fibralign is a privately held entity, sustained by a combination of investor backing and grant funding from institutions like the Department of Defense, National Institutes of Health (NIH), and the National Science Foundation. The firm has cultivated strategic partnerships with research universities and medical leaders to advance its product pipeline.
The core of Fibralign's product portfolio is its proprietary Nanoweave® technology. This platform enables the precise, three-dimensional printing of medical-grade type I collagen to create scaffolds that mimic the nanoscale structure of human tissue. This bio-scaffolding is designed to integrate with the body, providing a supportive micro-environment that encourages the body's natural repair functions and guides tissue regeneration without provoking a significant immune response. The technology is the result of over a decade of research into the assembly of fibrous proteins.
Fibralign's first commercialized product is the BioBridge® Collagen Matrix, a sterile, implantable surgical mesh. BioBridge is a thin, thread-like ribbon of highly purified porcine collagen designed to reinforce soft tissue. It is intended for use in surgical procedures to treat secondary lymphedema, a chronic and progressive disease that often results from cancer treatments and currently has no cure. Implanted through minimally invasive techniques, BioBridge acts as a scaffold to support the formation of new lymphatic vessels, bridging damaged areas and helping to restore lymphatic function. The device is biocompatible and designed to be fully resorbed by the body over time. BioBridge has received FDA 510(k) clearance, a CE Mark for the European market, and is being used by surgeons to treat both upper and lower limb lymphedema.
The company's business model revolves around the development and sale of these specialized medical devices to hospitals and surgical centers. Its revenue is generated through product sales. Fibralign engages with surgeons and healthcare providers who perform reconstructive and soft tissue repair procedures. The company is actively involved in clinical research to expand the applications of its technology, including studies for breast cancer-related lymphedema funded by a $3M grant from the National Cancer Institute. Beyond lymphedema, Fibralign is exploring a pipeline of future products for applications such as peripheral artery disease, nerve repair, and muscle regeneration.
Keywords: regenerative medicine, medical devices, tissue engineering, collagen scaffold, Nanoweave technology, BioBridge, lymphedema treatment, secondary lymphedema, soft tissue repair, surgical mesh, Stanford spin-out, lymphatic regeneration, implantable biomedical devices, therapeutic devices, reconstructive surgery, wound healing, cell migration, tissue integration, minimally invasive surgery, biocompatible materials